普罗普兰诺洛尔和其他β-阻断剂在甲状腺功能障碍症的治疗潜力
Weronika Szybiak-Skora1, Miłosz Miedziaszczyk2, Edyta Szałek2
1University Clinical Hospital in Poznan, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
International journal of molecular sciences
|September 13, 2025
概括
β-阻断剂有效地控制甲状腺功能障碍的症状,特别是在孕妇和患有阿米奥达龙并发症的患者中. 它们提供了一种安全的补充治疗选择,改善了患者的治疗结果.
科学领域:
- 内分泌学和药理学 在内分泌学和药理学
背景情况:
- 贝塔抑制剂在医疗专业中广泛使用.
- 它们降低了交感神经系统的反应性,有助于甲状腺功能障碍症的症状管理.
研究的目的:
- 审查β-阻断剂在甲状腺功能障碍治疗中的作用.
- 专注于特定的患者群体:孕妇,阳性甲状腺功能增强症和amiodarone后病例.
主要方法:
- 文献审查和知识总结.
主要成果:
- 普罗巴诺洛尔对神经精神病症状有效;选择性和非选择性β-阻断剂都能控制心脏症状.
- 贝塔抑制剂是孕妇甲状腺功能增强症患者的安全补充治疗方法.
- 它们用于阿米奥达龙后的甲状腺功能障碍并发症,并且可以作为阿米奥达龙的替代品.
- 贝塔抑制剂可以缓解甲状腺癌患者高剂量L-甲状腺素的症状,帮助维持TSH水平.
结论:
- β抑制剂在管理多样化的患者群体中的甲状腺功能障碍有价值.
- 它们的安全性支持在怀孕期间使用,以及在治疗与阿米奥达龙相关的甲状腺问题时使用.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Antihypertensive Drugs: Types of β-Blockers
1.5K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antihypertensive Drugs: Action of β1 Blockers
1.9K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.9K


